Theriva Biologics announced the first patient has been dosed in VIRAGE, the Phase 2b randomized, open-label, placebo-controlled, multicenter clinical trial of systemically administered VCN-01 in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3795 USD | +1.47% | +4.26% | -11.76% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.76% | 6.41M | |
+8.63% | 114B | |
+10.59% | 104B | |
-12.73% | 22.41B | |
-0.58% | 22.28B | |
-5.80% | 19.07B | |
-37.36% | 18B | |
-5.54% | 17.89B | |
+6.98% | 14.28B | |
+36.60% | 12.55B |
- Stock Market
- Equities
- TOVX Stock
- News Theriva Biologics, Inc.
- Theriva Biologics, Inc. Announces First Patient Dosed in VIRAGE, A Phase 2B Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma